Glucose monitoring is essential for the management of Type 1 diabetes but adds considerable treatment burden.
Intensive management might also result in a three-fold increase in hypoglycaemia, with much of this occurring during sleep. Continuous glucose monitoring that reduces some of this burden is available, but is extremely expensive.
Recently a third-party solution called MiaoMiao has been released that can convert a cheaper glucose monitoring system (the Abbott Freesytle Libre) into a fully functional continuous glucose monitor (MiaoMiao CGM). While exciting in concept, MiaoMiao CGM has no regulatory approval, and there is no current research into its function or safety. However, many patients are already adopting and purchasing this device independent of their medical team.
This world-first study aims to investigate MiaoMiao CGM using a gold standard randomised controlled crossover trial, during real life use in 55 young children (age 2-13 years) and their families; the population that may benefit the most from this sort of intensive glucose monitoring.
|Date||Thursday, 5 December 2019|
|Time||1:00pm - 2:00pm|
|Audience||Staff Only,Postgraduate Only|
|Event Category||Health Sciences|
|Department||Women's and Children's Health (Dunedin)|
|Location||Paediatric Seminar Rooms|
|Contact Name||Sarah-Jane Robertson|